Oncology

Study finds many patients not receiving radiation treatment.

Women who need bone-strengthening medications with an increased risk of endometrial cancer may benefit from nitrogen form of bisphosphonates.

American Cancer Society reports significant progress in death rates.

Targeted therapy found to shrink tumor growth.

Side effects found to make it harder for patients to concentrate.

Filgrastim is indicated to decrease the incidence of infection in patients with non-myeloid malignancies who also are receiving myelosuppressive anti-cancer drugs.

Hepatitis B vaccination reduces incidence of primary liver cancer by 84% later in life, study finds.

Many male patients being treated for prostate cancer undergo androgen deprivation therapy, which has been shown to have several risky side effects, including osteoporosis.

Drug currently being evaluated for treatment of hematological malignancies.

Researchers seek better targets for blocking events that lead to drug resistance.

Investigational drugs shut down critical genes and cancer cells responsible for tumor growth.

Experimental treatment effective in melanoma patients resistant to drugs that target BRAF.

Adding a building block found in DNA could aid healthy cell production in cancer patients, study finds.

Study finds drawing blood can be a powerful therapeutic in extracorporeal photopherisis.

Vaccine therapy stimulates immune defenses.

Ashley Feldt, PharmD, MBA, director of pharmacy, oncology at Aurora Health Care discusses how technology and remote medication preparation help improve oncology pharmacy.

Patients who received brentuximab vedotin post-transplant lived longer without disease progression than those on supportive care.

Nivolumab treats patients with unresectable or metastatic melanoma who no longer respond to other drugs.

Olaparib (Lynparza) was approved with companion diagnostic that detects mutations in BRCA genes.

Olaparib treats women with advanced ovarian cancer associated with defective BRCA genes.

Treatment shows promising anti-tumor activity.

Bayer HealthCare and Cardinal Health today announced the signing of a 15-year agreement for the contract manufacturing of Xofigo (radium Ra 223 dichloride). As part of the agreement, Cardinal Health will build a state-of-the art, 64,000 square foot facility in Indianapolis, which will be dedicated exclusively to the manufacturing of Xofigo. Product manufactured at this facility will primarily be distributed in the United States and Canada.

Recently approved drugs for the treatment of cancer include Cyramza, Sylvant, Zykadia, Beleodaq, Zydelig, and Keytruda.

Perjeta (pertuzumab) is now approved for the neoadjuvant treatment of breast cancer.

Understanding the needs of seniors with cancer and helping them to manage the complexities of the treatment process are essential to successful patient engagement and improved clinical outcomes.

FL118 could be effective in treating late stage cancers.

Researchers pinpoint method to reverse cancer cell resistance to chemotherapy.

Researchers find that negatives from daily aspirin outweigh the positives.

Ramucirumab receives third indication of 2014.

The FDA today approved a new indication for ramucirumab for the treatment of metastatic non-small cell lung cancer.